Cabozantinib and Pembrolizumab for Advanced Metastatic Melanoma

Cabozantinib and Pembrolizumab for Advanced Metastatic Melanoma

Publication date: May 21, 2019

The study aims to evaluate the safety and preliminary efficacy of the combination of cabozantinib and pembrolizumab in advanced melanoma

Concepts Keywords
Abdominal Surgery Melanoma Therapy
Abscess Melanoma Treatment
Adjuvant Disease diverticulitis cholecystitis
Adjuvant Therapy Brain metastases
Alcohol Carcinomatous meningitis
Antibodies HIV
Anticoagulants Hematemesis hematuria
Anticoagulation Tumor
Antihypertensive Active infection
Antineoplastic Treatment cabozantinib abscess
Appendicitis Positive Hepatitis HBsAg
Ascites Subjects brain metastases
Aspirin IV melanoma
Asthma Study hypothyroidism
Asymptomatic Concurrent uncontrolled hypertension
Atopy Bone metastasis
Autoimmune Clinically significant hemoptysis
Basal Conditions Cardiovascular disorders
Biological Therapy Reactive Hepatitis HCV
Biomarker Clinically significant disorders
Blood Previously severe hypersensitivity
Bone Fracture Hepatitis infections
Bowel Childhood asthma
Bowel Obstruction Metastatic Melanoma
BRAF Radiation therapy
Breast Minor surgery
Breastfeeding Antineoplastic therapy
Bronchodilators Major surgery
Carcinoma Hormone replacement
Cardiac Arrhythmias Chemotherapy
Central Nervous System Organ transplant
Cervix Biological therapy
Chemotherapy Adjuvant therapy
CHF Clinical medicine
Cholangitis Cancer treatments
Cholecystitis Antineoplastic drugs
Clopidogrel Oncology
Concurrent Breakthrough therapy
Congenital Radiation therapy
Congestive Heart Failure Adjuvant therapy
Corticosteroid Pembrolizumab
CYP3A4 Chemotherapy
Cytologically Melanoma
Diastolic Brain metastasis
Diverticulitis Radiation
ECG Antibodies
Esophagus Chemotherapy
Fistula Http
Formula MRI
Gastrointestinal Bleeding
Gastrointestinal Disorders
Gastrointestinal Perforation
HBsAg
HCV
Hematemesis
Hematuria
Hemoptysis
Hepatic Impairment
Hepatitis
Histologically
HIV
Hormone
Hypersensitivity Reaction
Hypertension
Hypothyroidism
Illicit Drugs
Immunosuppressive Agents
Immunosuppressive Medication
Indicative
Inducer
Infection
Informed Consent
Inhibitor
Intraluminal
Ischemic
Iupui
Lesion
Malabsorption Syndrome
Malignancy
Malignant
Medicine
Melanoma
Metastases
Metastatic
Molecular Weight
Monoclonal Antibody
MRI
Mucosa
Myocardial Infarction
Peptic Ulcer Disease
Perforation
Platelet
Prednisone
Pregnancy Test
Protocol
Pulmonary
Pulmonary Hemorrhage
Radiation Therapy
Radioactive
Radionuclides
Relapse
Serum
Small Molecule
Squamous Carcinoma
Steroid
Steroids
Stroke
Substance Abuse
Swallow
Syndrome
Systemic Therapy
Systolic
Teaspoon
Thrombin
Thromboembolic
Tolerability
Trachea
Transit
Tumor
Tyrosine Kinase Inhibitor
Ulcer
Ulcerative Colitis
Unstable Angina
Urine
Urine Test
Vaccine
Vitiligo
Warfarin

Semantics

Type Source Name
pathway BSID Melanoma
disease DOID Melanoma
disease MESH Melanoma
drug DRUGBANK Pembrolizumab
drug DRUGBANK Cabozantinib
disease MESH tumor
gene UNIPROT CD274
gene UNIPROT BRAF
gene UNIPROT MAP2K7
gene UNIPROT RPL17
gene UNIPROT PDCD1
disease MESH relapse
disease MESH ECG
gene UNIPROT PDCD1LG2
disease MESH diagnosis
disease DOID mucosal melanoma
disease DOID cancer
drug DRUGBANK Tropicamide
gene UNIPROT AES
disease MESH metastasis
disease MESH complications
drug DRUGBANK Prednisone
disease MESH carcinoma in situ
disease MESH carcinomatous meningitis
gene UNIPROT CYREN
disease MESH hypersensitivity
disease DOID hypersensitivity
disease MESH autoimmune disease
disease DOID autoimmune disease
disease MESH syndrome
disease DOID syndrome
disease MESH vitiligo
disease DOID vitiligo
disease MESH asthma
disease DOID asthma
pathway BSID Asthma
gene UNIPROT MS4A2
disease MESH hypothyroidism
disease DOID hypothyroidism
disease MESH infection
disease MESH Hepatitis B
disease DOID Hepatitis B
pathway BSID Hepatitis B
drug DRUGBANK Hepatitis B Vaccine (Recombinant)
disease MESH Hepatitis C
disease DOID Hepatitis C
pathway BSID Hepatitis C
gene UNIPROT BEST1
disease MESH substance abuse
disease DOID substance abuse
drug DRUGBANK Ethanol
drug DRUGBANK Warfarin
drug DRUGBANK Thrombin
drug DRUGBANK Clopidogrel
drug DRUGBANK Acetylsalicylic acid
disease MESH hematemesis
disease MESH hematuria
disease MESH bleeding
gene UNIPROT IK
gene UNIPROT DYRK3
gene UNIPROT CYP3A4
disease MESH Congestive heart failure
disease DOID Congestive heart failure
disease MESH hypertension
disease DOID hypertension
disease MESH congenital
disease MESH long QT syndrome
disease DOID long QT syndrome
disease MESH unstable angina pectoris
disease MESH cardiac arrhythmias
disease MESH stroke
disease DOID stroke
disease DOID TIA
disease MESH myocardial infarction
disease DOID myocardial infarction
disease MESH fistula
disease MESH ascites
disease DOID active peptic ulcer disease
disease MESH inflammatory bowel disease
disease DOID inflammatory bowel disease
disease MESH ulcerative colitis
disease DOID ulcerative colitis
disease MESH diverticulitis
disease DOID diverticulitis
disease MESH cholecystitis
disease DOID cholecystitis
disease MESH cholangitis
disease DOID cholangitis
disease MESH appendicitis
disease DOID appendicitis
disease MESH malabsorption syndrome
disease MESH gastric outlet obstruction
disease DOID gastric outlet obstruction
disease MESH intra-abdominal abscess
disease MESH abscess
gene UNIPROT FBXW7
drug DRUGBANK Polyethylene glycol
gene UNIPROT TUBE1
disease MESH ulcer
gene UNIPROT NR4A3
gene UNIPROT LITAF
drug DRUGBANK Prothrombin
drug DRUGBANK Creatinine
gene UNIPROT NR4A2
gene UNIPROT ALG3

Similar

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *